Cigna Group stock draws attention as growth meets a pharmacy squeeze
CI stock analysis and fair value · bull and bear case
The call: SageNoodle rates Cigna Group Fairly Valued: base-case fair value USD 305 against a price of USD 283, 8% above the quote on a 12 months horizon. There is no sourced explanation for today’s attention or price move; the latest verified operating update is the second-quarter report released July 30, 2026.
Cigna Group stock is getting fresh attention, but the evidence does not pin today’s move on a specific event. Its latest disclosed results show stronger earnings and a higher 2026 outlook alongside pressure in pharmacy-benefit profits.
Valuation as of 3 Oct 2026 · Quote currency: USD. Latest quote: Fri, 09 Oct 2026 19:15:29 GMT.
Written with AI from the linked sources and reviewed by a SageNoodle editor. How we work.
Latest quote
USD 282.57
At publication
USD 270.53
Fair value
USD 304.50
Upside
+7.8%
P/E at publication
11.2x
EV/EBITDA
Not available
FCF yield
Not available
ROIC Not available · Horizon 12 months
Why Cigna Group (CI) stock is mispriced
- 01
There is no sourced explanation for today’s attention or price move; the latest verified operating update is the second-quarter report released July 30, 2026.
- 02
Earnings growth and a raised 2026 outlook support the case for Cigna, but Evernorth’s pharmacy-benefit profit decline and a higher medical care ratio temper that progress.
- 03
At $270.53, the shares trade at 11.2 times trailing EPS; a preliminary $305 fair value assumes the company can deliver at least its adjusted 2026 outlook.
What Cigna Group does and how it makes money
The Cigna Group (NYSE: CI) sells health plans and health-service capabilities through Cigna Healthcare and Evernorth Health Services. Cigna Healthcare provides medical plans and related benefits to insured and self-insured clients in the U.S. and international markets; Evernorth includes pharmacy-benefit services and specialty and care services, such as drug claims administration, pharmacy networks, specialty medicines and clinical programs. In its July 30, 2026 release, the company reported 182.8 million total customer relationships at June 30, 2026 and sales capabilities in more than 30 markets and jurisdictions (second-quarter 2026 earnings release). Pharmacy Benefit Services links employers and health-plan clients with drug coverage and pharmacy networks; its margins depend on retaining contracts and managing the costs and economics of that service. Cigna Healthcare earns from medical coverage and related services, where premiums must cover claims and administration. The two models share customers and a corporate parent, but their immediate earnings drivers differ.
For the financial history and all coverage, see Cigna Group (CI) company research.
The cause of today’s attention is not established
Cigna Group stock is up 1.0% today at $270.53. That movement and a burst of headlines do not establish why it happened. Headlines point to the September 30 investor day and broader valuation discussion, but do not verify what the company announced there. Without a verified investor-day presentation or release, today’s attention cannot responsibly be attributed to a new strategy, spending plan or long-term target.
The latest verified operating news is Cigna’s July 30, 2026 second-quarter release. It reported revenue of $71.7 billion, up 7% from a year earlier, and raised its full-year adjusted income from operations outlook to at least $30.45 per share, an increase of $0.10 from the prior projection (second-quarter 2026 earnings release). That is useful context for the business, not proof of what moved the shares today.
The earnings mix is better than the pharmacy headline
Cigna’s adjusted income from operations increased 6% year over year in the second quarter, to $2.1 billion, or $7.78 per share. Cigna Healthcare’s adjusted operating income rose 17%, chiefly on an improved margin in its U.S. Employer business. Yet Evernorth, the large pharmacy and care-services business, saw adjusted revenue rise 6% while adjusted operating income fell 2%. Within it, Pharmacy Benefit Services revenue grew 8%, primarily due to drug mix, but adjusted operating income dropped 27%, which the company attributed primarily to client-focused initiatives, including large client contract renewals (second-quarter 2026 earnings release).
That is the central tension: activity and reported revenue can expand without a matching gain in profit. Cigna says the pharmacy investment is client-focused; shareholders need later results to show that retaining or renewing business pays off. Specialty and Care Services offers a counterweight: its adjusted operating income rose 22%, helped by specialty growth and operating efficiencies. The segment mix, not consolidated revenue alone, will decide whether growth translates into durable earnings.
The valuation leaves room for execution, not certainty
At $270.53, the shares trade at 11.2 times trailing EPS of $24.19. A base value of $304.50 uses Cigna’s 2026 adjusted EPS outlook floor of $30.45 and an analyst-assumed 10.0x multiple: $30.45 × 10.0 = $304.50, rounded to $305 per share. This is a scenario-based estimate, not a company forecast or a claim that adjusted EPS equals GAAP earnings. The company notes that its adjusted measure excludes items including investment gains, amortization and special items, and it cannot reconcile the forward outlook to GAAP earnings without unreasonable effort (second-quarter 2026 earnings release).
The bear-to-bull range is $245 to $365 per share, based on assumed adjusted EPS of $29 to $32 and assumed valuation multiples of 8.45x to 11.4x, respectively. The base case is $304.50, or $305 rounded. At this price, the stock is fairly valued against the base case, with 12.6% implied upside short of the 15% threshold for an undervalued rating. The valuation could look cheap if earnings compound, but the lower price multiple also reflects operating and execution risks.
What would change the long-term case
The July report supports, but does not settle, the long-term argument: second-quarter earnings grew and management raised its annual outlook, while pharmacy-benefit profits contracted and the medical care ratio increased to 84.5% from 83.2% a year earlier. Cigna attributed the ratio comparison primarily to higher prior-year risk-adjustment benefits in Individual and Family Plans recognized in the 2025 quarter, rather than presenting the change as a clean measure of underlying claims deterioration (second-quarter 2026 earnings release).
The next useful evidence is the company’s next reported quarter: whether Pharmacy Benefit Services stabilizes after client renewals, whether Cigna Healthcare manages medical costs within its stated 2026 medical care ratio outlook of 83.7% to 84.7%, and whether results support the adjusted EPS floor. The planned exit from Individual and Family Plans effective January 1, 2027 is also relevant to the health-plan mix, but Cigna has not quantified its financial effect in the second-quarter release. Until Cigna reports more, the headlines around strategy are attention, not proof of changed earnings power.
Follow SageNoodle on Google
Cigna Group revenue, margins and cash flow
Revenue (USD, billions)
Margins (%)
Free cash flow (USD, billions)
Estimated ROIC (%)
Net debt (USD, billions)
Monetary values are in USD; revenue, FCF and net debt are in billions; EPS is per share. Missing values appear as gaps and “Not available.” Source: SEC EDGAR XBRL filings, latest restated values; quarterly cash flow derived from year-to-date figures; Q4 = fiscal year minus nine months. ROIC is NOPAT (21% tax) over debt plus equity.
| Period | Revenue | Gross % | Op % | FCF | EPS | ROIC % | Net debt |
|---|---|---|---|---|---|---|---|
| FY2016 | 39.8 | Not available | 7.75 | 3.56 | 7.19 | Not available | Not available |
| FY2017 | 41.8 | Not available | 9.43 | 3.62 | 8.77 | Not available | Not available |
| FY2018 | 48.6 | Not available | 8.55 | 3.24 | 10.5 | 4.08 | 35.7 |
| FY2019 | 153.6 | Not available | 5.26 | 8.44 | 13.4 | Not available | Not available |
| FY2020 | 160.4 | Not available | 5.08 | Not available | 23.0 | Not available | Not available |
| FY2021 | 174.1 | Not available | 4.56 | Not available | 15.8 | Not available | Not available |
| FY2022 | 180.5 | Not available | 4.68 | Not available | 21.4 | Not available | Not available |
| FY2023 | 195.3 | Not available | 4.37 | Not available | 17.4 | Not available | Not available |
| FY2024 | 247.1 | Not available | 3.81 | Not available | 12.1 | Not available | Not available |
| FY2025 | 274.9 | Not available | 3.35 | Not available | 22.2 | Not available | Not available |
What Cigna Group management has said
Guidance
Paraphrased commentary
The Cigna Group’s outlook for full year 2026 consolidated adjusted income from operations is at least $30.45 per share.
Cigna Group fair value: bear, base and bull scenarios
Dot marks the latest quote of USD 282.57.
Bear
25%USD 245
Direct equity valuation using assumed adjusted EPS multiplied by an assumed P/E; quote currency USD.
Equity value USD 64.68B ÷ 0.264B diluted shares
- Adjusted EPS
- $29.00, analyst assumption below the company’s 2026 outlook floor
- P/E multiple
- 8.45x, analyst assumption
- Diluted shares
- 0.264 billion, analyst assumption based on reported weighted-average shares
The lower case assumes pharmacy-benefit earnings remain pressured and the business earns a lower multiple. The company’s outlook is management guidance, not a guaranteed result.
Base
55%USD 305
Direct equity valuation using assumed adjusted EPS multiplied by an assumed P/E; quote currency USD.
Equity value USD 80.39B ÷ 0.264B diluted shares
- Adjusted EPS
- $30.45, company’s 2026 outlook floor
- P/E multiple
- 10.0x, analyst assumption
- Diluted shares
- 0.264 billion, analyst assumption based on reported weighted-average shares
The base case uses the company’s minimum adjusted EPS outlook and a 10.0x assumed multiple. The unrounded calculation is $30.45 × 10.0 = $304.50 per share, rounded to $305.
Bull
20%USD 365
Direct equity valuation using assumed adjusted EPS multiplied by an assumed P/E; quote currency USD.
Equity value USD 96.31B ÷ 0.264B diluted shares
- Adjusted EPS
- $32.00, analyst assumption above the company’s 2026 outlook floor
- P/E multiple
- 11.4x, analyst assumption
- Diluted shares
- 0.264 billion, analyst assumption based on reported weighted-average shares
The upside case assumes the company exceeds its outlook floor, pharmacy-benefit earnings recover and the market assigns a higher multiple. Those are analyst assumptions, not disclosed company guidance.
Cigna Group (CI) stock: bullish vs bearish case
Bull case
- Second-quarter adjusted income from operations increased 6% year over year, and the company raised its 2026 adjusted EPS outlook floor.
- Cigna Healthcare and Specialty and Care Services reported higher second-quarter adjusted operating income.
- The TTM P/E of 11.2x leaves some valuation support if the company delivers its outlook.
Bear case
- Pharmacy Benefit Services adjusted operating income fell 27% year over year in the second quarter.
- Cigna Healthcare’s medical care ratio was higher than the year-earlier quarter, exposing the business to claims-cost and pricing execution risk.
- Cigna’s adjusted outlook is a non-GAAP measure that the company says cannot be reconciled to GAAP earnings on a forward-looking basis without unreasonable effort.
Cigna Group stock risks
| Risk | Severity | Probability | Rationale |
|---|---|---|---|
| Pharmacy contract economics | High | Medium | Pharmacy Benefit Services adjusted operating income fell 27% year over year in the second quarter, with the company citing client-focused initiatives including large contract renewals. |
| Medical claims and pricing | High | Medium | The Cigna Healthcare medical care ratio rose to 84.5% from 83.2% in the comparable quarter. The company’s full-year range is guidance and actual results may differ. |
| Adjusted earnings comparability | Medium | Medium | Management’s adjusted income measure excludes specified items and the company says it cannot provide a forward reconciliation to GAAP earnings without unreasonable effort. |
Cigna Group catalysts: what could move CI stock
- Next quarterly results; date not provided in the attached documentsNeutral
Next reported quarter
Check whether Pharmacy Benefit Services operating income stabilizes, whether medical costs remain within the full-year outlook range and whether Cigna maintains its adjusted EPS floor.
- January 1, 2027Neutral
Planned exit from Individual and Family Plans medical business
The company’s release says the planned exit is effective January 1, 2027, but does not quantify the earnings or revenue impact.
Cigna Group fair value history
| Period | Fair value | Verdict | Note |
|---|
Cigna Group news
Cigna Group stock: common questions
- Is Cigna Group (CI) stock undervalued or overvalued?
- SageNoodle rates Cigna Group Fairly Valued: base-case fair value USD 305 against a price of USD 283, 8% above the quote on a 12 months horizon. There is no sourced explanation for today’s attention or price move; the latest verified operating update is the second-quarter report released July 30, 2026.
- What is Cigna Group's fair value?
- Bear USD 245 (25% probability, Direct equity valuation using assumed adjusted EPS multiplied by an assumed P/E; quote currency USD.); Base USD 305 (55% probability, Direct equity valuation using assumed adjusted EPS multiplied by an assumed P/E; quote currency USD.); Bull USD 365 (20% probability, Direct equity valuation using assumed adjusted EPS multiplied by an assumed P/E; quote currency USD.). The base case uses the company’s minimum adjusted EPS outlook and a 10.0x assumed multiple. The unrounded calculation is $30.45 × 10.0 = $304.50 per share, rounded to $305.
- What is the bull case for CI stock?
- Second-quarter adjusted income from operations increased 6% year over year, and the company raised its 2026 adjusted EPS outlook floor. Cigna Healthcare and Specialty and Care Services reported higher second-quarter adjusted operating income. The TTM P/E of 11.2x leaves some valuation support if the company delivers its outlook.
- What is the bear case for CI stock?
- Pharmacy Benefit Services adjusted operating income fell 27% year over year in the second quarter. Cigna Healthcare’s medical care ratio was higher than the year-earlier quarter, exposing the business to claims-cost and pricing execution risk. Cigna’s adjusted outlook is a non-GAAP measure that the company says cannot be reconciled to GAAP earnings on a forward-looking basis without unreasonable effort.
- What are the biggest risks to Cigna Group stock?
- Pharmacy contract economics (High severity): Pharmacy Benefit Services adjusted operating income fell 27% year over year in the second quarter, with the company citing client-focused initiatives including large contract renewals. Medical claims and pricing (High severity): The Cigna Healthcare medical care ratio rose to 84.5% from 83.2% in the comparable quarter. The company’s full-year range is guidance and actual results may differ. Adjusted earnings comparability (Medium severity): Management’s adjusted income measure excludes specified items and the company says it cannot provide a forward reconciliation to GAAP earnings without unreasonable effort.
- What could move CI stock next?
- Next quarterly results; date not provided in the attached documents: Next reported quarter. Check whether Pharmacy Benefit Services operating income stabilizes, whether medical costs remain within the full-year outlook range and whether Cigna maintains its adjusted EPS floor. January 1, 2027: Planned exit from Individual and Family Plans medical business. The company’s release says the planned exit is effective January 1, 2027, but does not quantify the earnings or revenue impact.
Company reference pages
Browse company filings and market quotes to check the latest information. These pages update over time and are separate from the documents cited in this report.